View Document Preview and Link Document Date: 2009-05-29 17:19:46 Open Document File Size: 108,92 KB Share Result on Facebook
City Geneva / / Company Elsevier Science B.V. / / Continent Europe / Africa / Asia / North America / / Country Switzerland / France / Australia / United Kingdom / China / Germany / Italy / Belgium / United States / Spain / / Currency GBP / USD / / IndustryTerm Treatment of HBV / inactive carrier state / carrier state / unrecognised carrier / HBV therapy / inactive carrier / treatment of hepatitis B / / MedicalCondition acute hepatitis B / liver inflammation / HIV / HBV / hepatitis B. An / e.g. terminal renal failure / alcohol abuse / cirrhosis / hepatitis B / HDV hepatitis / Occult HBV infection / pre/post transplant infection / Nosocomial infections / hepatitis / severe chronic hepatitis / persistent hepatic inflammatory injury / liver disease / hepatic decompensation / HBV genotype / hepatitis B. If / discrete epidemics / chronic hepatitis D / cancer / hepatocellular carcinoma / HbeAg-positive chronic hepatitis / liver diseases / mild chronic hepatitis B / HCV / superinfection / active disease / mild hepatitis B. Patients / hepatitis D / compensated cirrhosis / severe hepatitis / infection / viral hepatitis / chronic hepatitis / HBeAg positive chronic hepatitis B / well compensated cirrhosis monitoring / chronic infection / acute liver disease / Fulminant hepatitis B / fibrosis / chronic carriers / hepatitis A / HBeAg negative chronic hepatitis / icteric hepatitis / well compensated cirrhosis / liver failure / HBeAg positive chronic hepatitis / severe chronic hepatitis D / severe chronic hepatitis B / mild chronic hepatitis / HDV infection / hepatic necrosis / fulminant hepatitis / HDV superinfection / obesity / mild disease / persistent inflammation / severe liver disease / infections / inflammatory activity / HBV carriers superinfection / perinatal infection / HBV infection / inactive cirrhosis / disease / simultaneous infection / HBeAg-negative chronic hepatitis / chronic HBV infection / severe acute hepatitis / tumour / inactive disease / HBeAg negative chronic hepatitis B / recurrent hepatitis B / negative chronic hepatitis B / HBV-related active liver disease / liver cancer / nosocomial infection / small tumours / liver injury / inflammation / chronic hepatitis B / encephalopathy / fluid retention / inactive liver disease / / MedicalTreatment highly active antiretroviral therapy / vaccination / immunosuppression / kidney transplant / HAART / antiretroviral therapy / mass vaccination / liver transplant / chemotherapy / Antiviral therapy / Immunosuppressive therapy / / NaturalFeature HBV-DNA falls / / Organization Oxford Centre for Evidence-Based Medicine / European Association for the Study of the Liver / EASL Jury / / Person Anna S. Lok / William Rosenberg / Dominique C. Valla / Juan Rode / Antonello Pietrangelo / Antoine Hadengue / Dominique-Charles Valla / George K.K. Lau / Roberto de Franchis / Neil McIntyre / Daniel Lavanchy / Gustav Paumgartner / Alfonso Mele / / Position President / Secretary / pathologist / / Product lamivudine / / Region Northwestern Europe / Mediterranean / Eastern Europe / / Technology genotyping / chemotherapy / genotype / alpha / antibodies / Ultrasound / transplantation / / URL www.elsevier.com/locate/jhep / http / SocialTag 
Journal of Hepatology–540 www.elsevier.com/locate/jhep Special article EASL INTERNATIONAL CONSENSUS CONFERENCE ON HEPATITIS B